Abstract: The present invention provides improved Pseudomonas Exotoxin A (PE) molecules with high cytotoxicity and reduced immunogenicity, compositions containing the improved (PE), and methods of use.
Type:
Grant
Filed:
September 10, 2010
Date of Patent:
January 20, 2015
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Ira H. Pastan, Richard Beers, Masanori Onda
Abstract: The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes.
Type:
Grant
Filed:
March 28, 2011
Date of Patent:
January 20, 2015
Assignee:
Ablynx N.V.
Inventors:
Francis Descamps, Maria Gonzalez Pajuelo, Pascal Gerard Merchiers, Catelijne Stortelers, Peter Vanlandschoot, Philippe Van Rompaey, Martine Smit, Regorius Leurs, David Andre Baptiste Maussang Detaille
Abstract: The invention relates to cellular localization signals. In particular, the invention relates to endoplasmic reticulum localization signals in monomeric or multimeric form. The localization signals are utilized as research tools or are linked to therapeutics. Disclosed are methods of making and using polypeptides and modified polypeptides as signals to localize therapeutics, experimental compounds, peptides, proteins and/or other macromolecules to the endoplasmic reticulum of eukaryotic cells. The polypeptides of the invention optionally include linkage to reporters, epitopes and/or other experimental or therapeutic molecules. The invention also encompasses polynucleotides encoding the localization signals and vectors comprising these polynucleotides.
Abstract: Techniques from two basic approaches, structure-based immunogen design and phage T4 nanoparticle delivery, are developed to construct new plague vaccines. The NH2-terminal ?-strand of F1 of Yersinia pestis is transplanted to the COOH-terminus of F1 of Yersinia pestis and the NH2-terminus sequence flanking the ?-strand of F1 of Yersinia pestis is duplicated to eliminate polymerization but to retain the T cell epitopes. The mutated F1 is fused to the V antigen of Yersinia pestis to thereby form a fusion protein F1mut-V mutant, which produces a completely soluble monomer. The fusion protein F1mut-V is then arrayed on phage T4 nanoparticles via a small outer capsid protein, Soc, from a T4 phage or a T4-related phage. Both the soluble and T4 decorated F1mut-V provided approximately 100% protection to mice and rats against pneumonic plague evoked by high doses of Yersinia pestis CO92.
Abstract: The present invention provides an antagonist of a Bcl-2 pro survival protein containing a BH3-like domain. The antagonist of the invention comprises ARTS and any fragment or peptide that comprises a BH3-like domain. The invention further provides compositions, combined compositions and kits as well as methods for treating Bcl-2 over-expressing disorders.
Type:
Application
Filed:
February 14, 2013
Publication date:
January 15, 2015
Applicant:
CARMEL-HAIFA UNIVERSITY ECONOMIC CORPORATION LTD.
Abstract: The present invention relates to a polymorphic MRP-1 polynucleotide, genes or vectors comprising the polynucleotides and a host cell genetically engineered with the polynucleotide or gene. Also provided are methods for producing molecular variant polypeptides, cells capable of expressing a molecular variant polypeptide and a polypeptide encoded by the polynucleotide or the gene or obtainable by the method or cells produced herein. Also provided is an antibody to the polypeptide, a transgenic animal, and a solid support comprising one or a plurality of the provided polynucleotides, genes, vectors, polypeptides, antibodies or host cells. Furthermore, methods of identifying a polymorphism, identifying and obtaining a pro-drug or drug or an inhibitor are also provided. In addition, the invention relates to methods for producing a pharmaceutical composition, diagnosing a disease and detection of the polynucleotide.
Type:
Application
Filed:
May 13, 2014
Publication date:
January 15, 2015
Inventors:
Ulrich Brinkmann, Sven Hoffmeyer, Esther Mornhinweg
Abstract: Engineered pesticidal polypeptides that are highly active against a wide range of pests and methods of making such polypeptides are disclosed. The nucleotide sequences encoding the pesticidal polypeptide can be used to transform various prokaryotic and eukaryotic organisms, which organisms can be used to produce the pesticidal polypeptides. The recombinant organisms and/or the polypeptides produced by the recombinant organisms can be used to control pests in various environments.
Type:
Application
Filed:
January 23, 2013
Publication date:
January 15, 2015
Applicant:
SYNGENTA PARTICIPATIONS AG
Inventors:
Mikyong Lee, Jeng Shong Chen, Cheryl Marie De Fontes, Jared Conville, Narendra Palekar
Abstract: The present invention provides a virus like particle comprising a virus structural protein and an antigen derived from PD-1 or a ligand of PD-1, and a composition or kit comprising thereof, its use in immune response etc.
Abstract: The present invention relates to methods and reagents for use in site-selective modification of proteins having lysine residues with functionalized peptides using a chemoenzymatic microbial transglutaminase-mediated reaction. The functionalized proteins may be used for study or therapeutic uses.
Type:
Application
Filed:
July 11, 2014
Publication date:
January 15, 2015
Inventors:
Aimee Usera, Zachary Robinson, Jennifer Cobb
Abstract: This disclosure relates to a method of preventing or treating a recurrence of acute otitis media in a subject at risk comprising administering a therapeutically effective amount of a composition, at least once to the subject.
Abstract: Abstract of the Disclosure Disclosed herein are methods and compounds for screening and identifying ligands of G protein-coupled receptors (GPCRs). Also disclosed are chimeric G proteins and methods for detecting the activation or inhibition of GPCRs.
Abstract: The present invention relates generally to a fusion protein made from a synthetic gene construct comprising of elements derived from the Leishmania antigens K26, K39, and K9. The fusion protein is particularly useful in the diagnosis of leishmaniasis, particularly visceral leishmaniasis in animals such as humans and dogs.
Abstract: A conformation-switching fluorescent protein probe for detection of alpha synuclein oligomers. The use of intrinsically disordered proteins as conformation-switching biosensors. The use of an alpha synuclein (?S) variant, PG65, together with conformation-sensitive fluorescence to create a molecular probe for rapid, specific and quantitative detection of ?S oligomers.
Abstract: Disclosed are mutants of galactosyltransferases that can catalyze formation of oligosaccharides in the presence of magnesium; mutants of galactosyltransferases having altered donor and acceptor specificity which can catalyze formation of oligosaccharides in the presence of magnesium; methods and compositions that can be used to synthesize oligosaccharides; methods for increasing the immunogenicity of an antigen; and methods to stabilize platelets.
Type:
Application
Filed:
March 10, 2014
Publication date:
January 15, 2015
Applicant:
The United States of America, as represented by the Secretary, Department of Health & Human Servic
Inventors:
Pradman K. Qasba, Elizabeth Boeggeman, Boopathy Ramakrishnan
Abstract: The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of Staphylococcus aureus. One embodiment of the present invention provides a method of generating an immune response in a mammal, that includes administering to the mammal, a composition having a chimeric protein having at least one of: a portion of a cholera toxin, a portion of a heat-labile toxin, and a portion of a shiga toxin; and an antigen having at least one of: an antigenic material from S. aureus and an antigenic material from a S. aureus-specific polypeptide.
Abstract: The present invention generally relates to the field of treatment of neuronal disorders and more particularly to neurotrophic factor MANF and uses thereof. The present invention provides a pharmaceutical compound comprising MANF nucleic acid molecule, MANF protein or a functional fragment thereof for the treatment of a peripherial neuropathy including Alzheimer's disease, Parkinson's disease, epilepsy, drug addiction and ischemic brain injury.
Type:
Application
Filed:
September 9, 2014
Publication date:
January 15, 2015
Applicant:
HERANTIS PHARMA, PLC.
Inventors:
Mart SAARMA, Päivi LINDHOLM, Merja VOUTILAINEN, Johan PERÄNEN, Raimo TUOMINEN, Mikko AIRAVAARA, Veli-Matti LEPPÄNEN, Maria LINDAHL, Jaan-Olle ANDRESSOO
Abstract: Disclosed is an oligopeptidic compound capable of interacting with proliferating cell nuclear antigen (PCNA), wherein the compound comprises a PCNA interacting motif which is: (SEQ?ID?NO.?28) [K/R]-[F/Y/W]-[L/I/V/A/M]-[L/I/V/A/M]-[K/R]; wherein the oligopeptidic compound has 9-70 subunits and comprises at least one signal sequence, wherein the signal sequence is a nuclear localization signal sequence and/or a cell penetrating signal sequence and wherein in said compound a PCNA interacting motif is N-terminal to a signal sequence. Also disclosed are methods of treatment of a disorder or condition where it is desirable to inhibit the growth of cells, or a method of treatment which involves cytostatic therapy, or a method of treatment of inflammation said method comprising administering the oligopeptidic compound to a subject in need thereof.
Type:
Application
Filed:
September 23, 2014
Publication date:
January 15, 2015
Inventors:
Marit OTTERLEI, Per Arne AAS, Emadoldin FEYZI
Abstract: Described herein are method(s), kit(s), reagent(s) and the like for determining von Willebrand factor (VWF) activity in a sample in the absence of ristocetin.
Abstract: The invention relates generally to chaperonin 10 N-terminal variants. More specifically, the invention relates to chaperonin 10 N-terminal variants with enhanced immunomodulatory capacity and/or enhanced binding affinity for pathogen-associated molecular patterns (PAMPs) and/or damage-associated molecular patterns (DAMPs).
Type:
Grant
Filed:
October 8, 2010
Date of Patent:
January 13, 2015
Assignee:
CBio Limited
Inventors:
Dean Jason Naylor, Richard James Brown, Christopher Bruce Howard, Christopher John De Bakker, Jeanette Elizabeth Stok, Andrew Leigh James, Daniel Scott Lambert, Kylie Jane Ralston, Walter Rene Antonius Van Heumen, Linda Allison Ward
Abstract: The present invention relates to a method for synthesizing templated molecules. In one aspect of the invention, the templated molecules are linked to the template which templated the synthesis thereof. The intion allows the generation of libraries which can be screened for e.g. therapeutic activity.
Type:
Grant
Filed:
December 9, 2008
Date of Patent:
January 13, 2015
Assignee:
Nuevolution A/S
Inventors:
Henrik Pedersen, Alex Haahr Gouilaev, Thomas Franch, Christian Klarner Sams, Eva Kampmann Olsen, Frank Abilgaard Sløk, Gitte Nystrup Husemoen, Jakob Felding, Lene Hyldtoft, Mads Nørregaard-Madsen, Michael Anders Godskesen, Sanne Schrøder Glad, Thomas Thisted, Per-Ola Freskgård, Anette Holtmann
Abstract: A hybrid complement-regulating protein comprises a first functional unit of a first complement regulatory protein having complement regulating properties, a first spacer sequence of at least about 200 amino acids encoding a polypeptide that does not exhibit complement regulating properties and at least a second functional unit attached to the spacer sequence. The second functional unit may be a polypeptide providing a functional unit of a second complement regulatory protein, a polypeptide derived from an immunoglobulin, or a polypeptide that enhances binding of the protein to an animal cell. The hybrid protein may also contain a second spacer sequence and a third functional unit of a complement regulatory protein, a polypeptide derived from an immunoglobulin, and a polypeptide that enhances binding of the protein to an animal cell. The optional third functional unit may be the same or different from the first or second functional units.
Abstract: The instant invention provides TCRs having one or more amino acid substitutions that bind to the AL9 epitope of the HIV protein vpr (AIIRILQQL (SEQ ID NO: 1)).
Type:
Grant
Filed:
March 25, 2010
Date of Patent:
January 13, 2015
Assignee:
Altor BioScience Corporation
Inventors:
Marilyn Fernandez, Bai Liu, Warren D. Marcus, Hing C. Wong
Abstract: Compositions that include a fusion protein comprising flagellin and at least one antigen that has an isoelectric point greater than about 7.0 and that is fused to at least one domain 3 of the flagellin activate Toll-like Receptor 5. Methods of stimulating an immune response, in particular, a protective immune response include administering a composition that includes an antigen fused to a loop of domain 3 of flagellin.
Type:
Grant
Filed:
June 28, 2013
Date of Patent:
January 13, 2015
Assignee:
VaxInnate Corporation
Inventors:
Langzhou Song, Ge Liu, Scott Umlauf, Uma Kavita, Hong Li, Xiangyu Liu, Bruce Weaver, Lynda Tussey
Abstract: Disclosed are pharmaceutical and synergistic compositions comprising human recombinant alpha-fetoprotein expressed in eucaryotic cells for preparation of therapeutic agents for use in oncology, immunotherapy, stem cell therapy and cosmetology and also for the diagnosis of cancer and embryonic pathologies.
Type:
Grant
Filed:
October 22, 2010
Date of Patent:
January 13, 2015
Inventors:
Elena Dudich, Lydia Semenkova, Igor Dudich, Eduard Tatulov
Abstract: The present invention relates to biologically active polypeptides linked to one or more accessory polypeptides. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications.
Type:
Grant
Filed:
August 15, 2008
Date of Patent:
January 13, 2015
Assignee:
Amunix Operating Inc.
Inventors:
Willem P. Stemmer, Volker Schellenberger
Abstract: Pseudomonas exotoxin A or “PE” is a 66 kD, highly potent, cytotoxic protein secreted by the bacterium Pseudomonas aeruginosa. Various forms of PE have been coupled to other proteins, such as antibodies, to generate therapeutically useful cytotoxin conjugates that selectively target cells of a desired phenotype (such as tumor cells). In the present invention, peptides spanning the sequence of an approximately 38 kD form of Pseudomonas exotoxin A protein were analyzed for the presence of immunogenic CD4+ T cell epitopes. Six immunogenic T cell epitopes were identified. Residues were identified within each epitope for introduction of targeted amino acid substitutions to reduce or prevent immunogenic T-cell responses in PE molecules which may be administered to a heterologous host.
Type:
Grant
Filed:
September 5, 2012
Date of Patent:
January 13, 2015
Assignee:
Intrexon Corporation
Inventors:
Timothy David Jones, Francis Joseph Carr
Abstract: The present invention relates to novel methods for making and refolding insoluble or aggregated proteins having free cysteines in which a host cell expressing the protein is exposed to a cysteine blocking agent. The soluble, refolded proteins produced by the novel methods can then be modified to increase their effectiveness. Such modifications include attaching a PEG moiety to form PEGylated proteins.
Type:
Grant
Filed:
September 29, 2010
Date of Patent:
January 13, 2015
Assignee:
Bolder Biotechnology, Inc.
Inventors:
Mary S. Rosendahl, George N. Cox, Daniel H. Doherty
Abstract: A process for the enantioselective enzymatic reduction of a keto compound of general formula I wherein R may represent any protective group for amino functions (tert. butyloxycarbonyl group (BOC), benzyloxycarbonyl group, 9-fluorenylmethoxycarbonyl group) and X?—Cl, —CN, —OH, Br, F.
Type:
Grant
Filed:
September 22, 2008
Date of Patent:
January 13, 2015
Assignee:
IEP GmbH
Inventors:
Antje Gupta, Maria Bobkova, Anke Tschentscher
Abstract: A method of using vaults as carrier molecules to deliver one or more than one substance to an organism, or to a specific tissue or to specific cells, or to an environmental medium. A vault-like particle. A method of preventing damage by one or more than one substance to an organism, to a specific tissue, to specific cells, or to an environmental medium, by sequestering the one or more than one substance within a vault-like particle. A method of delivering one or more than one substance or a sensor to an organism, to a specific tissue, to specific cells, or to an environmental medium. According to another embodiment of the present invention, there is provided a method of making vault-like particles, and making vault-like particles comprising one or more than one substance, or one or more than one sensor.
Type:
Grant
Filed:
October 15, 2008
Date of Patent:
January 13, 2015
Assignee:
The Regents of the University of California
Inventors:
Leonard H. Rome, Valerie A. Kickhoefer, Raval-Fernandes Sujna, Phoebe L. Stewart
Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
Type:
Grant
Filed:
September 12, 2013
Date of Patent:
January 13, 2015
Assignee:
Bristol-Myers Squibb Company
Inventors:
Sharon Cload, Linda Engle, Dasa Lipovsek, Malavi Madireddi, Ginger Chao Rakestraw, Joanna Swain, Wenjun Zhao, Martin J. Corbett, Alexander T. Kozhich
Abstract: The presently disclosed and claimed inventive concepts include inhibitors of antiplasmin cleaving enzyme (APCE) and fibroblast activation protein alpha (FAP) which can be used in various therapies related to disorders of fibrin and ?2-antiplasmin and abnormal cell proliferation. The presently disclosed and claimed inventive concepts also include substrates of APCE and FAP, which may be used, for example, in screening methods for identifying such inhibitors. The presently disclosed and claimed inventive concepts further include, but are not limited to, methods of treating or inhibiting atherosclerosis and thrombus disorders by altering the ratios of types of plasma ?2-antiplasmin and to methods of treating conditions involving abnormal cell proliferation such as cancers.
Type:
Grant
Filed:
December 15, 2010
Date of Patent:
January 13, 2015
Assignee:
The Board of Regents of the University of Oklahoma
Inventors:
Patrick A. McKee, Kenneth W. Jackson, Kyung N. Lee, Victoria J. Christiansen
Abstract: The disclosure relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual has for developing pre-eclampsia based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers. The disclosure also relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual is carrying a fetus having a chromosomal abnormality based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers.
Type:
Grant
Filed:
December 31, 2013
Date of Patent:
January 13, 2015
Assignees:
Wallac Oy, The Fetal Medicine Foundation
Abstract: Quantitation of analytes, including but not limited to peptides, polypeptides, and proteins, in mass spectrometry using a labeled peptide coupled to a reporter, and a universal reporter.
Type:
Grant
Filed:
July 7, 2011
Date of Patent:
January 13, 2015
Assignee:
Thermo Fisher Scientific GmbH
Inventors:
Joel Louette, John Charles Rogers, Scott M. Peterman, Bruno Domon, Elodie Duriez
Abstract: The present invention relates to a compound which is a polysaccharide derivative of EPO, or of an EPO like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.
Type:
Grant
Filed:
June 24, 2014
Date of Patent:
January 13, 2015
Assignee:
Lipoxen Technologies Limited
Inventors:
Sanjay Jain, Peter Laing, Gregory Gregoriadis, Norbert Oskar Rumpf
Abstract: This application is based, inter alia, on the discovery of a binding interaction between the Hn-33 hemagglutinin polypeptide of the type A Clostridium botulinum neurotoxin complex and synaptosomal proteins, including synaptotagmin II (Syt II). Methods of screening for compounds that modulate, e.g., increase or decrease, this interaction are provided. Also provided are compositions and methods for targeting compounds to neuronal and cancer cells by coupling the compounds to Hn-33 or biologically active Hn-33 variants.
Abstract: Methods and systems for creating a genetic construct, a protein, and a polymer comprising a domain swapping module. A domain swapping module is a fusion protein in which a lever protein, which has a long amino (N) to carboxy (C) terminal distance, is inserted into a surface loop of an assembler protein, thereby stretching the assembler protein and splitting it into two fragments held apart by the lever so that they cannot rejoin. If the assembler protein is split at the proper location, the fragments will recombine with their respective counterparts from either one or more different—but similarly-split—assembler proteins.
Type:
Application
Filed:
December 27, 2012
Publication date:
January 8, 2015
Applicant:
The Research Foundation For The State University Of New York
Inventors:
Stewart Loh, Jeung-hio Ha, Diana Mitrea
Abstract: An assay for identifying ligands of the ?1 receptor based on a fusion protein comprising the ?1 receptor flanked by two fluorophores, so that said fluorophores are capable of producing constitutive FRET when no ligand is bound to the ?1 receptor. The fusion protein of the invention also allows the simultaneous determination whether the newly determined ligand is an agonist or an antagonist. Said fusion protein has been expressed in a cell, giving rise to a new cellular model useful for identifying ?1 receptor ligands, and additionally for discriminating between agonists and antagonists.
Type:
Application
Filed:
January 9, 2013
Publication date:
January 8, 2015
Inventors:
Javier Burgueño-Hurtado, Francisco Ciruela Alférez, José Miguel Vela Hernández
Abstract: Embodiments of the present disclosure provide for enzyme sensors, protease sensors, methods for producing and using the enzyme and protease sensors, methods of detecting and/or measuring protease activity, methods for characterizing protease cellular activity, fusion proteins, polynucleotides, and vectors corresponding to the enzyme and protease sensors, kits, and the like.
Abstract: Nutritive proteins are provided. In some embodiments the nutritive proteins comprise a first polypeptide sequence comprising a fragment of a naturally-occurring nutritive protein. In some embodiments the fragment comprises at least one of a) an enhanced ratio of branch chain amino acid residues to total amino acid residues present in the nutritive protein; b) an enhanced ratio of leucine residues to total amino acid residues present in the nutritive protein; and c) an enhanced ratio of essential amino acid residues to total amino acid residues present in the nutritive protein.
Type:
Application
Filed:
March 15, 2013
Publication date:
January 8, 2015
Inventors:
David Arthur Berry, Brett Adam Boghigian, Nathaniel W. Silver, Geoffrey von Maltzahn, Rajeev Chillakuru, Michael Hamill
Abstract: The present invention relates to a three-dimensional structure of a complex explored by crystallization of the complex of NanR which is a key pathogenic regulatory protein of Vibrio vulnificus and ManNA6P which is a NanR regulator. Further, the present invention relates to a modified NanR protein, a polynucleotide encoding the protein, a vector including the polynucleotide, and a transformant including the vector. Furthermore, the present invention relates to a method for screening a substance regulating interaction between NanR and the transcriptional control region of nan operon which is a gene cluster regulated by NanR, or a substance regulating interaction between NanR and ManNAc-6P, by designing three-dimensional structure of the complex, and to an antibacterial composition including the screened substance.
Type:
Application
Filed:
June 20, 2014
Publication date:
January 8, 2015
Inventors:
Sang Ho Choi, Byoung Sik Kim, Myung Hee Kim, Jung Won Hwang
Abstract: This invention concerns compositions and methods of treating or diagnosing inflammatory disorders and other disorders, as well as compositions and methods of treating HIV.
Type:
Grant
Filed:
April 13, 2012
Date of Patent:
January 6, 2015
Assignee:
Rutgers, The State University of New Jersey
Abstract: The present invention provides methods and compositions useful in the diagnosis and management of autoimmune diseases. In particular, the present invention provides improved methods and compositions for the diagnosis and management of Graves' disease. The methods of the present invention not only avoids the need for radioactivity and are much simpler, economical, and rapid than methods traditionally used for the diagnosis of Graves' disease, but also improve upon the sensitivity and detection abilities of previous luciferase-based autoantibody detection assays.
Abstract: Disclosed is a human serum albumin (HSA) linker and HSA linker with binding, diagnostic, and therapeutic agents conjugated thereto. Also disclosed is a conjugate in which the HSA linker is covalently bonded to amino and carboxy terminal binding moieties that are first and second single-chain Fv molecules (scFvs). Exemplified conjugates are useful, e.g., in reducing tumor cell proliferation, e.g., for therapeutic therapeutic applications. Also disclosed are methods and kits for the diagnostic and therapeutic application of an HSA linker conjugate.
Type:
Grant
Filed:
October 14, 2009
Date of Patent:
January 6, 2015
Assignee:
Merrimack Pharmaceuticals, Inc.
Inventors:
Charlotte McDonagh, Michael Feldhaus, Alexandra Huhalov
Abstract: The present application describes an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and TNF polypeptide comprising: (a) a nucleotide sequence encoding a TNFR2 component and VEGFR1 component operatively linked to (b) a nucleotide sequence encoding a multimerizing component, wherein the TNFR2 component consists essentially of a nucleotide sequence encoding the amino acid sequences of cystein rich domain 1, cystein rich domain 2, cystein rich domain 3, and cystein rich domain 4 of the extracellular domain of TNFR2, and wherein the VEGFR1 component consists essentially of a nucleotide sequence encoding the amino acid sequences of Ig-like domain 2 of the extracellular domain of VEGFR1.
Type:
Grant
Filed:
December 11, 2009
Date of Patent:
January 6, 2015
Assignee:
Korea Advanced Institute of Science and Technology (KAIST)
Inventors:
Keehoon Jung, Young Jun Koh, Gyun Min Lee, Sun Chang Kim, Gou Young Koh
Abstract: The present invention relates to novel conjugate complexes for immunoassays as well as kits comprising these conjugate complexes, methods of producing these complexes, and methods of detecting an analyte by use of these complexes. The conjugate complexes of the invention comprise one or more non-nucleic acid receptors capable of specifically binding an analyte, one or more nucleic acid markers comprising a predetermined nucleotide sequence, one or more first linker molecules capable of specifically binding the non-nucleic acid receptor and the nucleic acid marker, and one or more second linker molecules capable of specifically binding the first linker molecules.
Abstract: Embodiments of the invention are related to a polypeptide comprising the amino acid sequence of a human IgE-Fc C?3-C?4, wherein said C?3-C?4 starts at amino acid 328 and ends at amino acid 547 of said IgE-Fc, and wherein C 328 is A and K 367 is C. Other embodiments concern a second polypeptide comprising the amino acid sequence of a human Fc?RI? extracellular region, wherein said extracellular region starts at amino acid 1 and ends at amino acid 176 of said Fc?RI?. Still other embodiments are related to a method of identifying a compound that inhibits the binding of an IgE-Fc to a Fc?RI?, said method comprising: contacting the polypeptide, wherein said IgE-Fc C?3-C?4 sequence is labeled with a fluorophore, and the second polypeptide, with a test compound; and determining whether binding of said polypeptide to said second polypeptide is decreased in the presence of said test compound.
Type:
Grant
Filed:
March 29, 2011
Date of Patent:
January 6, 2015
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Abstract: Methods and compositions for modifying the metabolism of a subject are provided. One embodiment provides a recombinant polypeptide having a polynucleotide-binding domain, a protein transduction domain, and a targeting domain. In a preferred embodiment, the polynucleotide-binding domain includes one or more HMG box domains.